Shares of Incyte Corporation (NASDAQ:INCY – Get Free Report) passed below its fifty day moving average during trading on Wednesday following insider selling activity. The stock has a fifty day moving average of $118.78 and traded as low as $117.76. Incyte shares last traded at $117.80, with a volume of 1,211,021 shares.
Specifically, EVP Lee Heeson sold 10,694 shares of the firm’s stock in a transaction dated Friday, November 13th. The stock was sold at an average price of $120.82, for a total value of $1,292,049.08. Following the transaction, the executive vice president owned 26,884 shares in the company, valued at $3,248,124.88. This trade represents a 28.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Wall Street Analysts Forecast Growth
A number of research analysts have issued reports on INCY shares. Guggenheim upped their target price on shares of Incyte from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. TD Cowen lifted their price target on shares of Incyte from $138.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. Barclays boosted their price target on shares of Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Benchmark restated a “buy” rating on shares of Incyte in a report on Tuesday, October 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Incyte in a research note on Tuesday, October 27th. Eleven investment analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. Based on data from MarketBeat, Incyte has an average rating of “Hold” and a consensus target price of $133.86.
More Incyte News
Investors following INCY have been watching these news items:
- Positive Sentiment: The European Commission approved Povofortay (povorcitinib) as the first once-daily oral treatment for adults with moderate-to-severe hidradenitis suppurativa (HS) in Europe. Approval opens a new commercial opportunity, though the reports provide no sales forecast or launch details. Incyte approval announcement
- Positive Sentiment: Piper Sandler maintained its Buy rating on Incyte, signaling continued analyst confidence, although the provided report does not include a revised price target or new rationale. Piper Sandler rating report
- Neutral Sentiment: EVP Lee Heeson sold 10,694 shares worth about $1.29 million, reducing his direct holdings by 28.46%. The trade was made under a pre-arranged Rule 10b5-1 plan, making it a less definitive signal about his outlook for Incyte. Insider sale report
Incyte Stock Performance
The company has a market capitalization of $24.01 billion, a price-to-earnings ratio of 62.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.78. The company has a 50-day moving average price of $118.78 and a 200-day moving average price of $109.23.
Incyte (NASDAQ:INCY – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.93) by $0.33. The business had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.46 billion. Incyte had a net margin of 6.71% and a return on equity of 7.92%. Incyte’s revenue for the quarter was up 14.0% on a year-over-year basis. During the same period last year, the company posted $2.26 EPS. As a group, sell-side analysts anticipate that Incyte Corporation will post 2.29 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Trails Edge Capital Partners LP bought a new position in Incyte during the 2nd quarter worth $17,570,800. Tidal Investments LLC lifted its position in shares of Incyte by 33.4% during the 2nd quarter. Tidal Investments LLC now owns 102,834 shares of the biopharmaceutical company’s stock valued at $11,657,000 after acquiring an additional 25,768 shares during the period. BlackRock Inc. bought a new stake in shares of Incyte during the 2nd quarter valued at $2,044,189,000. Mediolanum International Funds Ltd grew its holdings in shares of Incyte by 25.4% during the 1st quarter. Mediolanum International Funds Ltd now owns 60,300 shares of the biopharmaceutical company’s stock worth $5,447,000 after purchasing an additional 12,227 shares in the last quarter. Finally, State of Wyoming acquired a new stake in shares of Incyte during the 2nd quarter worth $4,027,000. 96.97% of the stock is owned by institutional investors and hedge funds.
Incyte Company Profile
Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.
Featured Articles
- Five stocks we like better than Incyte
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
